Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al

ANNALS OF THE RHEUMATIC DISEASES

BMJ PUBLISHING GROUP

1. ZonMw, 2Treat [436001001]